Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334451 · ClinicalTrials.gov registry record
RAPID-RF: Remote Active Monitoring in Patients With Heart Failure
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 891
- Enrollment target
NCT00334451: Completed study, sponsored by Boston Scientific Corporation.
NCT00334451 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 891 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00334451 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 891 participants
- Enrollment target
Study Summary
The RAPID-RF Registry aims to characterize LATITUDE® Patient Management's alert feature: LATITUDE Active Monitoring™ by evaluating type and frequency of alert notifications and alert-related medical interventions. This registry will also assess clinical outcomes including quality of life and New York Heart Association Class changes over time, mortality, hospitalizations and heart failure-related event rates.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 891 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-07 |
What the finished NCT00334451 record still lists
NCT00334451 is an observational study that tracks outcomes without assigning an intervention. The registered 891 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00334451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00334451 about?
NCT00334451 is a clinical study titled "RAPID-RF: Remote Active Monitoring in Patients With Heart Failure". The RAPID-RF Registry aims to characterize LATITUDE® Patient Management's alert feature: LATITUDE Active Monitoring™ by evaluating type and frequency of alert notifications and alert-related medical interventions. This registry will also assess clinical outcomes including quality of life and New Yor...
What is the current status of trial NCT00334451?
This trial is currently completed. The enrollment target is 891 participants. The study started on 2006-05. Estimated completion is 2008-07.
Who is sponsoring clinical trial NCT00334451?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia